Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Cyril-Konto"

3 News Found

Glenmark, Ichnos Sciences form ‘Ichnos Glenmark Innovation’ for new drug discovery in cancer treatment
News | January 30, 2024

Glenmark, Ichnos Sciences form ‘Ichnos Glenmark Innovation’ for new drug discovery in cancer treatment

This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors

Ichnos Sciences inks agreement with Astria Therapeutics for OX40 antagonist monoclonal antibody portfolio
News | October 13, 2023

Ichnos Sciences inks agreement with Astria Therapeutics for OX40 antagonist monoclonal antibody portfolio

Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications

Glenmark subsidiary, Ichnos Sciences and Almirall enter exclusive licencing agreement
Biotech | December 14, 2021

Glenmark subsidiary, Ichnos Sciences and Almirall enter exclusive licencing agreement

Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales

Latest Stories

Cipla invests additional Rs. 26 crore in Achira

Granules India posts Q4 FY24 consolidated PAT at Rs. 129.64 Cr

Ind-Swift posts Q4 FY24 consolidated PAT at Rs. 37.53 Cr

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging